Significant progress has been made in the clinical management of a variety of cardiovascular diseases. Nevertheless, the therapeutic efficacy of the current treatment modalities for atherosclerosis and restenosis is not fully sufficient in a large proportion of patients. One of the major contributing factors is the clinical and biological heterogeneity of these still life-threatening diseases, which involve processes that we do not fully understand at the moment. Over the past decades, it has become increasingly clear that part of the gene-environmental interactions relevant for complex diseases is regulated by epigenetic mechanisms such as histone acetylation and DNA methylation. Epigenetic processes modulate gene expression patterns without modifying the actual DNA sequence and have profound effects on the cellular repertoire of expressed genes. They contribute to the expression of genes that play a key role in extracellular matrix formation, inflammation, and proliferation, processes involved in cardiovascular pathologies such as atherosclerosis and restenosis.
Introduction Atherosclerosis and restenosis
Atherosclerosis and restenosis are multifactorial processes, which have several corresponding features and share some risk factors such as diabetes and hypertension. Both processes are in a significant part characterized by an inflammatory response to injury of the endothelium, which causes reshaping of the vessel wall in size and composition, called vascular remodelling. Furthermore, they share proliferation and migration of vascular smooth muscle cells (VSMCs) and elaboration of extracellular matrix, leading to accumulation of collagen and proteoglycans.
Despite these similarities, there are also important differences in the cause and progression of atherosclerosis and restenosis. Atherosclerosis develops partly in response to elevated lipoprotein levels and cigarette smoke, whereas restenosis is mainly an overshooting wound healing response to vascular injury by balloon dilatation or stent placement. This restenotic process is not particularly sensitive to circulating lipids, and smokers even seem to have a reduced risk for restenosis. 1 Furthermore, atherosclerosis is, in contrast to restenosis, characterized by the accumulation of oxidized lipoproteins, both within foam cells and extracellularly. Although development and progression of atherosclerosis is associated with ageing, the restenotic process is relative rapidly induced after revascularization interventions such as balloon dilatation or stent placement. Currently, atherosclerosis and restenosis are still serious health problems, which we do not yet fully understand. It is therefore important to search for factors that cause and contribute to the development of the processes involved in these diseases.
Investigation into the exact mechanisms of the disturbed lipoprotein metabolism, inflammation, proliferation, and migration of smooth muscle cells and vascular remodelling will offer us more opportunities for prediction, diagnosis, and finally treatment.
Because clinical risk factors do not fully predict the development of atherosclerosis and restenosis, it is important to search for genes that determine susceptibility to these risk factors. A positive family history is a major risk factor for cardiovascular disease, and twin studies have shown that death from coronary artery disease at an early age of one twin is a strong predictor of the risk in the other twin. 2 As reviewed by Nordlie et al., 3 many genes in lipid metabolism, vascular homeostasis, hemostasis, and inflammation have been found to be related to coronary artery disease. Although observed associations were not always replicated by other studies, their review emphasizes the importance of genetics in atherosclerotic disease. Moreover, the multifactorial nature of the disease suggests a role for many other, yet uninvestigated genes. Previous research from our department has demonstrated the importance of genetics in restenosis after percutaneous coronary interventions (PCIs). Polymorphisms in several inflammatory genes, such as tumour necrosis factor-a (TNF-a), eotaxin, CD14, granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-10 (IL-10), caspase-1, and also noninflammatory genes such as lipoprotein lipase, stromelysin-1 (MMP3), and the b-adrenergic receptor have been found to be associated with the risk for restenosis. 4 -7 In the past decade, research into cardiovascular diseases has been focused on the identification of these genetic factors. It has become clear, however, that part of the gene-environmental interactions relevant for complex diseases in which inflammation, proliferation, and remodelling play an important role is regulated by epigenetic mechanisms such as histone acetylation and DNA methylation.
Epigenetics, the study of non-DNA sequence-related heredity, can help to explain the relationship between an individual's genetic background, the environment, ageing, and disease. Thus, a review of the possible role of epigenetics in complex diseases such as atherosclerosis and restenosis seems appropriate and is presented here.
Epigenetics
Epigenetic processes modulate gene expression patterns without modifying the actual DNA sequence and have profound effects on the cellular repertoire of expressed genes. 8 It is well known that epigenetic processes can lead to meiotically and mitotically heritable changes in gene expression and play an important role in the control of cell identity. Two well-known examples of epigenetic mechanisms are methylation of DNA at CpG dinucleotides and modification or rearrangement of nucleosomes, which include covalent post-translational modifications of histone tails. 9, 10 Both processes can be influenced by environmental factors and affect gene function without changing the DNA sequence. In contrast to classical mendelian views on inheritance, epigenetics also focuses on the heredity of environmental effects, which leads to DNA modifications other than DNA sequence variation, a phenomenon that is called 'epigenetic inheritance'.
An increasing number of findings from both human and animal studies support the existence of epigenetic inheritance and show that DNA methylation is the main responsible mechanism. 11, 12 Inheritance of DNA methylation is regulated by the enzyme DNA methyltransferase 1 (Dnmt I), which is known to copy methylation patterns during semi-conservative DNA replication. 13 Although a similar mechanism has not yet been discovered for post-translational histone modifications, they are likely to be maintained through cell division. Not only methylation of DNA, but also acetylation of histones has been shown to accumulate in time. 8 Older monozygotic twins were found to have larger differences in DNA methylation and histone acetylation when compared with younger twin pairs. This finding also demonstrates that post-translational histone modifications can be influenced by environmental factors. Despite the lack of an evident mechanism of maintaining posttranslational histone modifications during cell division, modification of histone tails is by many considered an epigenetic process. 14, 15 Epigenetic modifications of histone tails include acetylation, methylation, ubiquitination and SUMOylation of lysine residues, phosphorylation of serine residues, and methylation of arginines. The various histone modifications form a code that is read by nonhistone proteins and have varying effects on chromatin structure and gene accessibility. 9 As a rule of thumb, conformationally relaxed chromatin (euchromatin) is a hallmark of potentially active genes and is associated with hypomethylation of CpG dinucleotides in DNA and acetylated histones. Compact chromatin (heterochromatin) is associated with transcriptionally silent genes and is associated with DNA hypermethylation at CpG dinucleotides and non-acetylated histones. These chromatin modifications are exerted by epigenetic regulators such as DNA methyltransferases (Dnmts), histone acetyltransferases (HATs), and histone methyltransferases (HMTs), which are increasingly being implicated as direct or indirect components in the regulation of expression of vascular, immune, and other (tissue)-specific genes. A great promise of epigenetics is that it offers new targets for therapy in cardiovascular disease. Epigenetic processes are reversible by nature, which is underscored by the counterbalancing action of HATs and histone deacetylases (HDACs) and of HMTs and histone demethylases, and are required for fine-tuning of gene expression for fundamental cellular processes such as cell proliferation and differentiation. This offers the prospect of pharmacological inhibition of the various enzymatic activities involved in epigenetic DNA and histone modifications, which is aimed at the induction or silencing of transcription of disease relevant genes. In addition to the possibility of modifying the effects of deleterious genes, it might be possible to influence the effects of environmental risk factors.
As HATs and HDACs are involved in fundamental processes that regulate the expression of multiple genes, they most likely play an important role in the multifactorial processes that lead to atherosclerosis and restenosis. Therefore, it is important to identify those HATs and HDACs that play a role in the transcriptional regulation of genes, the products of which contribute to the processes involved in neointima formation and atherogenesis, such as inflammation, smooth muscle cell proliferation, and matrix formation. In this review, we will discuss the role of HATs and HDACs in the transcriptional regulation of genes that play a critical role in inflammation, proliferation, and matrix formation, processes which are thought to be pathognomonic for atherosclerosis and restenosis development.
Histone acetyltransferase and histone deacetylases
Gene expression is regulated by acetylation of core histones through the action of HATs by transfer of an acetyl group to the e-portion of lysine residues. Hyperacetylation of histones results in an open modification of chromatin structure and affects gene transcription through accessibility of DNA to the basal transcription initiation machinery ( Figure 1) . 17 -19 Conversely, gene repression is mediated via HDACs and other corepressors, which remove the acetyl groups from hyperacetylated histones and counteract the activity of HATs resulting in a closed chromatin structure. These nuclear enzymes have been shown to regulate the expression of inflammatory genes by modifying chromatin structure. 20 HATs are recruited to promoters by gene regulatory proteins that interact with specific recognition sequences in DNA and in this way control gene transcription. This is exemplified by the transcriptional control of MHC-II genes, in which the class II transactivator (CIITA), a component of the promoter-assembled enhanceosome, provides the platform for recruitment of HAT and HDAC activities. 21 -23 At the moment, a large variety of HATs have been identified, which can be divided in several families, including the PCAF/ Gcn5, p300/CBP, MYST, SRC, TAF II 250, HAT1, and ATF-2 families. The HATs within these families show high sequence similarity, but there is poor similarity between these families. 24 All HAT proteins vary in their HAT domains and their substrate specificity, but have the common feature that they require the assembly of multiprotein complexes for nucleosomal acetylation. 25 Their precise substrate specificity even depends on the context of these multisubunit HAT complexes. 26 The HDAC enzymes are zinc-dependent aminohydrolases, which can be grouped into different classes. 27 Class I HDACs (HDACs 1-3 and 8) are widely expressed, reside almost exclusively in the nucleus, and are known to modulate cell proliferation and survival. Class II HDACs (HDACs 4-7, 9, and 10) have a more restricted distribution, are able to move between the nucleus and the cytoplasm in response to certain cellular signals, and may be involved in cellular differentiation. 27, 28 Class II HDACs can be further divided in subclasses IIa (HDACs 4, 5, 7, and 9) and IIb (HDACs 6 and 10). Class IIa members form a distinct group because of the presence of an extended N-terminal regulatory domain, 29 whereas HDACs 6 and 10 contain an extra catalytic domain. 30 The most recently discovered isoform is HDAC 11, which constitutes class IV. 31 A different NADþ-dependent family consists of sirtuins (SIRT 1 -7), which are thought to be involved in the apoptosis of mononuclear cells. 32, 33 The different HDACs are likely to be regulated differently. HDACs interact with corepressor molecules such as nuclear receptor corepressor and ligand-dependent corepressor, NuRD, and mSin3, all of which aid HDACs in gene repression and may provide specificity by selecting which genes are switched off by HDACs. 34, 35 Furthermore, HDAC activity is associated with the action of polycomb group proteins, 36 which play a key role in gene silencing and maintenance of cellular identity. Besides their role in histone acetylation, HATs are also found to act as factor acetyltransferases (FATs), which acetylate many nonhistone proteins, 37 such as p53, which is directly acetylated by PCAF, 38, 39 CBP and p300, 40, 41 and nuclear factor kappa B (NFkB), which is acetylated by CBP and p300. 42, 43 Acetylation of these proteins often results in increased DNA binding and transcriptional activity. 37 Accumulating evidence suggests that many
HDACs can deacetylate these non-histone proteins. For example, HDAC3 is known to deacetylate the p65 subunit of NFkB, promoting association with IkBa, which leads to IkBadependent nuclear export of NFkB. 44 Furthermore, HDAC1 has been shown to deacetylate p53 in vitro and in vivo. 45 As many other non-histone proteins are also known to be targeted by HATs and HDACs, their influence on gene expression is not necessarily dependent on chromatin remodelling. Changes in gene expression, which are caused by alterations in the activity of HATs or HDACs, can therefore not automatically be regarded as epigenetic. Over the past years, several HAT and HDAC inhibitors have been identified. These inhibitors mechanistically affect the action of HATs and HDACs. The large variety of HDAC inhibitors that have been discovered or developed can be divided into structural classes ( Table 1) . 27, 46, 47 Early phase clinical trials have demonstrated that inhibitors from all different classes seem to be well tolerated and exhibit clinical activity against several human neoplasms. 27 In the next paragraphs, we will discuss the role of HATs and HDACs in inflammatory, proliferative, and remodelling processes associated with atherosclerosis and restenosis. Furthermore, we will discuss the potential applicability of HAT and HDAC inhibitors in disease management.
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Inflammation, the role of histone acetyltransferase and histone deacetylases Nuclear factor kappa B Atherosclerosis and restenosis are for a major part determined by inflammation. 5, 48 The expression of multiple inflammatory genes is regulated by pro-inflammatory transcription factors such as NFkB. The transcription factor NFkB plays a role in the orchestration, amplification, and perpetuation of the inflammatory response and forms the molecular basis of chronic inflammation. 49 -51 HATs and HDACs have been implicated in modulating NFkB activity. In unstimulated cells, NFkB is found in the cytoplasm associated with its inhibitor protein called IkB, which masks the nuclear translocation signal and prevents NFkB from entering the nucleus. 52 Upon cell stimulation with various NFkB inducers, including reactive oxygen species (ROS) and lipid peroxidation products, IkB is rapidly phosphorylated and thereby targeted for ubiquination. 53, 54 The released NFkB dimer is translocated to the nucleus and activates target genes by binding with high affinity to kB elements in their promoters. 55, 56 This process is known to be activated by Adapted from Santini et al., 27 Drummond et al., 46 and Monneret. and to induce histone acetylation, thus leading to an increase in the NFkB-mediated expression of inflammatory genes such as GM-CSF and IL-8 ( Figure 2) . 58, 59 Furthermore, p300 has been shown to enhance angiotensin II-induced IL-6 expression in rat VSMCs, a process that is also mediated by NFkB. 60 Also, PCAF is known to be required to coactivate p65-dependent transcription and has been shown to activate the transcription of several NFkB-regulated genes known to be involved in cardiovascular disease. Spermidine/spermine N1-acetyltransferase 2 (SSAT2) has been found to cooperate with CBP and PCAF to enhance TNF-a-induced NFkB activity. 61 Furthermore, Miao et al. 62 demonstrated that PCAF could enhance the p65-mediated increase in TNF-a promoter activity and that high glucose increased the recruitment of PCAF to the TNF-a and cyclooxygenase-2 (COX-2) promoters. They demonstrated concomitant acetylation of specific lysine residues of histones H3 and H4 at these promoters. As TNF-a and COX-2 have been implicated in the development of both atherosclerosis 63, 64 and restenosis, 4,65 PCAF may play a role in the development of these diseases. A role for PCAF in vascular disease was recently confirmed by findings from our department, showing that the 22481 G/C polymorphism in the promoter of the PCAF gene is significantly associated with all-cause mortality in the PROSPER study (manuscript in preparation, abstract published in Circulation 2007;116:II_40). The minor C allele was associated with a significant survival advantage, whereas this allele was also found to protect against clinical restenosis after a PCI in the GENDER study.
In line with the findings showing a role for HATs in NFkB-mediated transcriptional activation, HDACs have been shown to reverse this process and to repress NFkB-mediated gene expression. 66, 67 Furthermore, HDAC inhibition by trichostatin A (TSA) was found to increase basal and TNF-a-induced expression of the NFkB-regulated IL-8 gene, whereas expression of HDAC1 and HDAC2 repressed TNF-induced NFkB-dependent gene expression. 67 In addition to its ability to associate with HATs and HDACs, the p65 component of NFkB is also a direct target for acetylation and deacetylation. PCAF and CBP/p300 appear to acetylate specific lysine residues on the p65 subunit of NFkB, increasing its DNA binding and causing transcriptional activation (Figure 2) , whereas HDAC3 has been shown to deacetylate NFkB and promote its association with the inhibitor IkBa within the nucleus, in order to promote export into the cytoplasm and thus terminate the activity of NFkB. 42, 44, 68, 69 Granulocyte macrophage-colony stimulating factor
Several findings indicate the importance of GM-CSF in atherosclerosis and restenosis. Administration of GM-CSF has been shown to prevent the progression of atherosclerosis in Watanabe heritable hyperlipidaemic rabbits. 70 Furthermore, in a rabbit model of restenosis, GM-CSF injections have been shown to reduce neointima formation. 71 In further support of a role for GM-CSF Figure 2 The role of p300/CREB binding protein (CBP)-associated factor (PCAF) in the activation of nuclear factor kappa B (NFkB)-mediated transcription. The figure illustrates the dual role of p300, CBP, and PCAF in the activation of NFkB-mediated transcription upon cell stimulation with NFkB-inducers such as reactive oxygen species (ROS), tumour necrosis factor (TNF)-a, or interleukin (IL)-1b. These coactivators act as histone acetyltransferases (HATs) at the site of NFkB-regulated genes. Furthermore, they act as factor acetyltransferases (FATs) and appear to acetylate the p65 subunit of NFkB, increasing its DNA binding and causing transcriptional activation also by this mechanism.
in the development of restenosis, variation in the GM-CSF gene has been shown to be related to the risk of restenosis in a large patient population undergoing PCI. 5 Because of its role in atherosclerosis and restenosis, it is of interest to note that the NFkB-mediated, inflammatory signalling-induced hyperacetylation of histone H4 also correlated with an increased expression of GM-CSF. The HDAC inhibitor TSA was found to lead to an increased expression of GM-CSF and IL-8 in alveolar macrophages and airway epithelial cell lines after activation with inflammatory stimuli.
58,72,73
Eotaxin Eotaxin, an eosinophil chemoattractant important in inflammatory responses, has already been shown to play a role in atherosclerotic disease. Eotaxin plasma levels were found to be associated with angiographic coronary artery disease, 74 and human atherosclerotic plaques were found to express increased quantities of eotaxin mRNA. 75 Furthermore, the A23T polymorphism in the eotaxin gene is associated with the risk for myocardial infarction, 76 and the 21328 A allele was found to decrease the risk for restenosis after PCI.
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Inflammatory signalling by TNF-a induces selective histone H4 acetylation and binding of p65 to the eotaxin promoter as determined by chromatin immunoprecipitation (ChIP), resulting in eotaxin gene transcription. 77 Notably, the ChIP analysis also revealed that beta(2)-agonists and glucocorticoids were able to reduce transcription of eotaxin by inhibiting both TNF-a-induced histone H4 acetylation and recruitment of p65 to the eotaxin promoter, without altering the capability of NFkB to translocate to the nucleus.
Cyclooxygenase-2
Several proteins that have been implicated in the development of cardiovascular disease have been studied more extensively in cancer and inflammatory diseases. This is exemplified by Cox-2, a protein that may be associated with the development of atherosclerosis 64 and restenosis, 65 which plays an important role in colon carcinogenesis and inflammation. 78 Cox-2 expression can be induced by several cytokines, including TNF-a, and the HDAC inhibitors sodium butyrate (NaBu) and TSA were found to repress Cox-2 mRNA and resulting protein synthesis in a colon cancer cell line (HT-29). 79 Although HDAC inhibition by NaBu is known to suppress cytokine-induced NFkB activation, and NFkB binding sites exist within the Cox-2 promoter, this repression of Cox-2 expression in HT-29 cells was not mediated by a lower Cox-2 promoter activity, but was related to mRNA stabilization. 79 These observations infer that besides a direct effect of HDAC inhibitors on gene promoter activity, additional cellular mechanisms exists, which contribute to the modulation of mRNA expression and protein levels of Cox-2.
Reactive oxygen species
Activated inflammatory cells and a perturbation of lipoprotein metabolism are key factors in atherogenesis. The oxidative modification of lipids is involved in the recruitment of mononuclear leukocytes to the arterial intima. Furthermore, activated leukocytes, as well as endothelial mitochondria, can produce ROS, which are associated with endothelial dysfunction. 80 Elevated intracellular ROS are generated under various physiological and pathological conditions involving oxidative stress, including inflammation, ischaemia, reperfusion, and sepsis. The biological effects resulting from oxidative stress are in part mediated by modifications in HAT and HDAC activities, which lead to alterations in histone acetylation levels and resulting NFkB activation. 28, 52, 81 Several in vitro experiments have shown that hydrogen peroxide increases HAT activity 73 and decreases HDAC activity, 57, 82 leading to an increase in histone acetylation and expression of inflammatory mediators.
The role of ROS in chromatin remodelling is further illustrated by the observed imbalance in expression levels of HATs and HDACs in bronchial biopsies from patients with asthma, when compared with airways of non-asthmatic subjects. 83 Notably, treatment with inhaled steroids resulted in increased HDAC activity and reduced HAT activity in subjects with asthma, thereby influencing this imbalance. This is in accordance with other studies, describing that recruitment of HDAC activity to activated transcriptional complexes was required for glucocorticoid repression of inflammatory genes. 58, 84 In addition, the glucocorticoid receptor also acts as a direct inhibitor of CBP-associated HAT activity. 58 This could be a mechanism that explains the effectiveness of glucocorticoids in suppressing inflammation in asthma. Together, there are several lines of evidence that suggest an important role of altered histone acetylation levels in inflammatory processes, which are associated with atherosclerosis and restenosis.
Proliferation of (vascular)smooth muscle cells and histone acetylation Serum response factor
Precise control of SMC gene transcription plays a major role in vascular development and pathophysiology. Vascular SMCs undergo profound changes in their phenotype during neointima formation in response to vessel injury or within atherosclerotic plaques. 85 Serum response factor (SRF) is an important mediator in transcriptional activation of genes that exhibit SMC-restricted expression. SRF exerts its activation through binding to CArG box DNA sequences found within regulatory elements of these genes. Recent findings indicate that binding of this factor is influenced by chromatin structure. In vitro and in vivo experiments have shown that SRF binding is associated with patterns of posttranslational histone modifications that are specific to the SMC lineage, including di-methylation of lysine residues 4 and 79 in histone H3, acetylation of lysine 9 in histone H3, and acetylation of histone H4. In particular, deacetylation of histone H4 was coupled with loss of SRF binding to CArG box DNA during suppression of SMC differentiation in response to vascular injury. 86 SRF-mediated transcriptional activation is enhanced by myocardin, which acts as a co-activator, through interaction with the MADS box of SRF. Myocardin is specifically expressed in cardiac and smooth muscle cells and plays a critical role in the differentiation of SMCs through activation of SMC-specific genes by tethering to CArG boxes with SRF. 87 The promyogenic activity of myocardin is enhanced by p300, a HAT that associates with the transcription activation domain of myocardin. 87 Conversely, class II HDACs interact with a domain of myocardin distinct from the p300-binding domain and suppress smooth muscle gene activation by myocardin.
Hypernuclear acetylation
Hypernuclear acetylation (HNA) plays a role in proliferation, differentiation, and apoptosis. 88 Using an antibody against e-acetylated lysine, increased histone acetylation was observed in VSMCs in coronary atherosclerotic lesions, whereas it was not present in normal coronary arteries. Furthermore, thrombin, a humoral factor known to cause activation and proliferation of VSMCs, strongly potentiates HNA in cultured VSMCs. In thrombin-induced HNA of VSMCs, the MAP kinase pathway and the CBP are implicated. 89 It suggests that coactivators cooperating with signal-dependent transcription activators play a role in atherosclerogenesis via HNA in VSMCs.
Cell-cycle regulators
Because HDACs also modulate histone acetylation levels at the site of genes involved in cell-cycle control, they have also been implicated in the proliferation of SMCs. 90, 91 This is illustrated by the observation that TSA was found to inhibit SMC proliferation via induction of p21waf1. 92 Activity of p21waf1 is known to induce cell-cycle arrest in VSMCs 93 -96 and A20, an NFkBdependent gene that has been shown to inhibit proliferation of VSMCs via increased expression of p21waf1 has been shown to prevent neointima formation after balloon angioplasty in a rat model of carotid artery stenosis. 97 In addition, PCAF could play a role in the suppression of VSMC proliferation by its ability to directly acetylate p53. 38, 39 It has been shown to activate p53-responsive enhancer elements within the p21waf1 promoter. 39 Moreover, HDAC8 was found to be exclusively expressed in cells showing smooth muscle differentiation, including visceral and VSMCs, myoepithelial cells, and myofibroblasts, and is mainly detected in their cytosol. 98 Until recently, it was thought that its activity was restricted to the nucleus, with histones as a unique substrate.
Remodelling: extracellular matrix formation and chromatin dynamics
Inappropriate remodelling of the vessel wall in response to a variety of stimuli, including haemodynamic changes, inflammation, and tissue injury, is currently thought to be causative to the development of atherosclerosis and restenosis. Matrix metalloproteinases (MMPs) comprise a family of structurally related proteins, which includes collagenases, stromelysin, and gelatinases. They have the collective capability to degrade components of the extracellular matrix and to act as mediators in a variety of cell signalling pathways through degradation of non-matrix proteins. MMP expression is strongly enhanced in vascular pathologies and is therefore thought to contribute to the disease process. This is illustrated by the observation that enhanced expression of MMP2 and MMP9 (also referred to as gelatinase A and gelatinase B) is noted in vulnerable regions of human carotid plaques in association with macrophages. 99 Furthermore, as reviewed by Newby, 100 induction of MMP9 and activation of MMP2 occur rapidly after balloon injury in multiple animal models. Additional evidence for an important role of MMP2 and MMP9 in vascular remodelling comes from knockout mouse models of these gelatinases, which showed reduced VSMC migration and less neointima formation after arterial injury. 101 -104 Increased MMP3 (also referred to as stromelysin-1) expression has been linked to plaque rupture. 99, 105 In addition, several studies investigating the MMP3 5A/6A promoter polymorphism have shown that the risk of myocardial infarction is higher in patients carrying the 5A allele, which is associated with increased MMP3 levels. [106] [107] [108] [109] [110] and MMP13 are also associated with cardiovascular disease. MMP1 was found to be expressed in human atherosclerotic lesions and not in unaffected blood vessel walls. 111 Moreover, the MMP1 1G/2G polymorphism at position 21607 of the transcriptional start site, which is associated with a higher promoter activity, reduces the risk for coronary artery disease. 111 Likewise, the MMP13 277 A/G polymorphism is associated with atherosclerosis in the abdominal aorta of black males.
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Owing to their essential role in vessel wall remodelling, MMPs could become prime targets for pharmacological interference in various pathological conditions that exhibit increased or decreased MMP levels and resulting excessive or reduced matrix degradation.
In the next sections, we will discuss the role of the chromatin environment in expression of the various MMPs in vascular pathologies.
Matrix metalloproteinase-2 and -9 (gelatinase A and gelatinase B)
Epigenetic mechanisms have been implicated in the regulation of transcription and/or functional expression of MMP2 and MMP9. This is underscored by several observations showing modulation in expression levels of MMPs following exposure of cells to different HDAC inhibitors in various cell types. Treatment of different tumour cell lines with NaBu resulted in the modulation of secreted expression levels of MMP2 and MMP9, which was accompanied by global histone H4 hyperacetylation. 113 In contrast, it was demonstrated that increased histone acetylation by TSA-treated 3T3 cells decreases mRNA as well as zymographic activity of MMP2. 114 This TSA-induced inhibition of MMP2 activation is mediated via upregulation of the glycoprotein RECK. 115 With respect to MMP9, it has been demonstrated that IFN-g induced a reduction in MMP9 expression, which is mediated by CIITA. CIITA is induced by IFN-g through the JAK/Stat signalling pathway, and downregulation of MMP9 is exerted by CIITA through sequestering of CBP from the MMP9 promoter, effectively reducing histone H3 acetylation, explaining the inhibition in MMP9 transcription by IFN-g. 116 Further support for a role of epigenetic mechanisms in the regulation of MMP9 expression comes from the observation that the metastases-associated gene MTA1 represses MMP9 expression, in part by the recruitment of HDAC2 to the distal MMP9 promoter region 117 and modulation of the activity of MMP9 by depsipeptide in uveal melanoma cells.
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Matrix metalloproteinase-3 (stromelysin-1)
Besides MMP2 and MMP9, several findings also indicate the involvement of epigenetic mechanisms in the expression of MMP3. Overexpression of the translocation-ETS-leukaemia (TEL) protein, which specifically associates with HDAC3, represses transcription of the stromelysin-1 gene. A role for HDAC3 in the TELmediated repression was supported by the observations that histone H3 was underacetylated near the TEL-binding sites in the stromelysin-1 promoter and that administration of TSA impaired TEL-dependent repression of the stromelysin-1 promoter.
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A role for histone acetylation in MMP3 expression is further supported by the findings that NaBu selectively enhanced protein production and mRNA expression of stromelysin-1 in TNF-a-or IL-1b-stimulated mesenchymal cells. 120 Furthermore, it has been demonstrated that the transcription factors Ets-1 and Ets-2 recruit p300 and CBP to the human stromelysin-1 promoter to activate transcription.
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Matrix metalloproteinase-1 and -13 (collagenase 1 and collagenase 3)
Histone acetylation modifications are also implicated in the expression of MMP1 and MMP13. This notion is derived from studies in chondrocytes, which revealed that exposure of cells to TSA or NaBu blocks the induction of MMP1 and MMP13 by pro-inflammatory cytokines at both the mRNA and protein levels. 122 Furthermore, NaBu treatment of liver cancer cells results in decreased transcription of MMP1. 123 Additional evidence for a role of histone acetylation modifications in the control of MMP1 expression is derived from the observation that the co-activator p300 has been shown to relieve the Smad-mediated inhibitory effect of TGF-b in cytokine-induced MMP1 expression in dermal fibroblasts. 124 Expression of MMP1 is also indirectly affected by TSA and suberoylanilide hydroxamic acid through inhibition of c-jun. 125 Together, histone acetylation modifications have been shown to play a direct and indirect role in the regulation of MMP expression, critical mediators in vascular remodelling and as such implicated in the pathology of atherosclerosis and restenosis.
Conclusions and future directions
Besides genetic control, epigenetic mechanisms contribute to the expression at the transcriptional level of genes, the products of which play a key role in extracellular matrix formation, inflammation, and proliferation as discussed in this review. Altered expression levels of these genes have been observed in cardiovascular pathologies, and therefore it is thought that these aberrant expression patterns contribute to the processes associated with atherosclerosis and restenosis. As the nucleotide composition of genes is not altered by these epigenetic processes and alterations in chromatin structure are reversible, these epigenetic modifications are amendable to pharmacological intervention, which may prove to be an effective treatment modality for the management of cardiovascular diseases.
Although chromatin modifications exist at the level of DNA methylation at CpG dinucleotides and a variety of posttranslational histone modifications, we have focused on the role of histone acetylation modifications exerted by HATs and HDACs in cardiovascular disease. Besides accumulation of epigenetic modifications in ageing, histone acetylation modifications are also dynamic: rapid alterations in the levels of histone acetylation modifications can be measured after cell activation by a variety of external stimuli. It can therefore be envisioned that similar alterations in histone acetylation modifications are induced in the response to cellular injury such as inflicted by, for example, flow shear stress or by balloon angioplasty. As detailed in the various preceding sections of this review, there is ample experimental evidence from different cellular models that indeed the activities of HATs and HDACs are key elements, either directly or indirectly, in the transcriptional control of vascular disease-associated genes. Aberrant expression of these chromatinmodifying activities therefore has a profound effect on the overall level of transcription of disease-associated genes and function of their products in the processes involved in extracellular matrix formation, inflammation, and proliferation.
Clinical feasibility of applying drugs that inhibit the activity of HATs and HDACs is demonstrated in the application of these compounds in the treatment of cancer and neurological disorders. 27 However, it should be realized that application of these compounds can also result in non-specific activation of genes and other genomic elements not only in diseased cells but also in normal cells. Especially, the use of non-specific inhibitors that target many different HATs or HDACs can be expected to have broad effects on gene expression and may inflict potential harmful side effects. It is therefore important to identify those HATs and HDACs that play a role in the transcriptional regulation of cardiovascular disease-associated genes and to develop specific inhibitors that target these HATs and HDACs. As also a single HAT or HDAC family member can be involved in the transcription of multiple genes, even specific inhibitors could have unwanted effects on gene expression. However, each of these family members could have some degree of specificity to a set of genes acting together in a vascular disease-associated process. Although HATs and HDACs are known to be substrate-specific, it is thus far not known if they can also be specific to certain processes. Nevertheless, many HDAC inhibitors appear to be well tolerated in patients, and local application of these epigenetic modifiers would overcome the side effects that are inheritably linked with systemic application.
Several recent investigations indeed indicate that HDAC inhibition may be beneficial in vascular disease-associated processes. Transcription of the CYP7A1 gene encoding cholesterol 7a-hydroxylase, an enzyme involved in the intra-hepatic conversion of cholesterol to bile acids, is known to be repressed by bile acids as part of a feedback regulatory mechanism. Recent findings demonstrate that the bile acid-mediated repression of this gene was caused by an increase in the nuclear concentration of HDAC7, which promoted the assembly of a repressive complex at the CYP7A1 promoter. 126 Notably, treatment of low density lipoprotein (LDL)-receptor knockout mice with the HDAC inhibitors TSA and valproic acid elevated Cyp7a1 mRNA levels and consequently reduced total plasma and LDL-cholesterol dramatically. In addition to these findings, in vitro experiments showed that TSA strongly inhibited SMC proliferation and TNF-a production by activated macrophages, processes with an important role in atherogenesis. 127 Interesting in this context is the recent finding that also statins inhibit HDAC activity. Lovastatin was found to induce p21 expression through dissociation of HDAC1/ 2 and association of CBP, leading to histone-H3 acetylation at the site of the p21 promoter. 128 Therefore, part of the beneficial effect of statins in vascular disease might be due to its role in these mechanisms. Recent findings from Granger et al. 129 also identify HDACs as possible targets for therapy in cardiovascular disease. They showed, utilizing a standard murine model of ischaemia-reperfusion, that ischaemia induces HDAC activity in the heart, resulting in deacetylation of histones H3 and H4. Within a treatment window from 1 h before ischaemia until 45 min after reperfusion, the HDAC inhibitors TSA and scriptaid were able to reverse the induction of ischaemia-induced HDAC activity in vivo and to reduce myocardial infarct size by 50%. Furthermore, a 5 h period of hypoxia induced a strong decrease in acetylated histones H3 and H4 in mouse cardiomyocytes in vitro, which could be completely blocked by TSA. The finding that HDAC inhibition can reduce the size of myocardial infarction in mice by half, even when treatment is applied after reperfusion, has important implications for the potential application of these compounds in the context of acute coronary syndromes.
In conclusion, over the past years, it has become increasingly clear that besides genetic components, also epigenetic components contribute to the aetiology of cardiovascular disease. Dynamic interactions of the environment and the epigenome determine accessibility of genes, which have profound effects on their transcription and function. A further understanding on the role of epigenetic processes in cardiovascular disease processes such as atherosclerosis and restenosis might provide novel opportunities to understand disease pathology. This would provide the necessary knowledge platform for design of alternative treatment strategies, which are aimed at interfering in these epigenetic processes for the management of atherosclerosis and restenosis.
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